Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Meheco To Acquire Huali Jiuzhou

This article was originally published in PharmAsia News

Executive Summary

China Meheco will pay RMB 80 million to acquire 100 percent stake of Beijing Huali Jiuzhou Medicine, a major health care product distributor jointly owned by HolleyPharm and Zhejiang Hua Li Medicine Investment Group. The move represents China Meheco's attempt to shift from a foreign medical trading enterprise to an integrated foreign and domestic trading company. With the acquisition, it can quickly establish drug distribution channels in the nation's major cities to cover almost all grade-three hospitals. This has a strategic significance for the firm to seize domestic market share. When the deal is completed, China Meheco's core business revenue will increase by RMB 1 billion, elevating its position in the local pharmaceutical sector. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts